Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities

Nader Hirmas(Deutsches Konsortium für Translationale Krebsforschung), Wolfgang P. Fendler(Essen University Hospital), Marc Ingenwerth(Deutschen Konsortium für Translationale Krebsforschung), Christine Hanoun(Essen University Hospital), Ken Herrmann(Klinikum rechts der Isar), Stefan Kasper(Essen University Hospital), Claudia Kesch(Essen University Hospital), Miriam Sraieb(Deutsches Konsortium für Translationale Krebsforschung), Bastian von Tresckow(University of Cologne), Hans‐Ulrich Schildhaus(University of Cologne), Waldemar Uhl(Ruhr University Bochum), Kim M. Pabst(Klinik und Poliklinik für Nuklearmedizin), Katharina Lueckerath(German Cancer Research Center), Lukas Kessler(German Cancer Research Center), Marco Niedergethmann(University Medical Centre Mannheim), Martin Stuschke(Essen University Hospital), Jens T. Siveke(German Cancer Research Center), Céline Lugnier(Ruhr University Bochum), Hubertus Hautzel(Deutsches Konsortium für Translationale Krebsforschung), Boris Hadaschik(Essen University Hospital), Rainer Hamacher(Technical University of Munich), Philipp Harter, Michael Nader(Deutsches Konsortium für Translationale Krebsforschung), Clemens Aigner(Essen University Hospital), Francesco Barbato(Deutsches Konsortium für Translationale Krebsforschung), Martin Glas(University of Bonn), Sherko Kümmel(Kliniken Essen-Mitte), Viktor Grünwald(Essen University Hospital)
Journal of Nuclear Medicine
December 29, 2022
10.2967/jnumed.122.264689
Cited by 68

Related Papers

Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
|Journal of Clinical Oncology|2006|464